Pacira Pharmaceuticals Director Sells $6,032,269 in Stock (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) Director Andreas Wicki sold 55,813 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $108.08, for a total transaction of $6,032,269.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded down 0.54% during mid-day trading on Wednesday, hitting $107.13. The stock had a trading volume of 233,689 shares. Pacira Pharmaceuticals has a 52 week low of $36.02 and a 52 week high of $108.50. The stock’s 50-day moving average is $94.83 and its 200-day moving average is $80.34. The company’s market cap is $3.845 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.04 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.25. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $42.20 million. Pacira Pharmaceuticals’s revenue was up 175.2% compared to the same quarter last year. On average, analysts predict that Pacira Pharmaceuticals will post $0.23 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Wedbush raised their price target on shares of Pacira Pharmaceuticals from $98.00 to $110.00 in a research note on Friday, August 1st. Separately, analysts at Canaccord Genuity raised their price target on shares of Pacira Pharmaceuticals to $114.00 in a research note on Friday, August 1st. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Friday, August 1st. They now have a $109.00 price target on the stock, up previously from $86.00. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Pacira Pharmaceuticals has an average rating of “Buy” and a consensus price target of $104.68.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.